Zelboraf ® Safety Study (ZeSS)

• Research type

  Research Study

• Full title

  ZeSS: A Prospective Observational Safety Study of Patients with BRAFV600 Mutation-positive Unresectable or Metastatic Melanoma Treated with Vemurafenib (Zelboraf®)

• IRAS ID

  123019

• Contact name

  Mark Harries

• Contact email

  mark.harries@gstt.nhs.uk

• Sponsor organisation

  Roche Group

• REC name

  London - Stanmore Research Ethics Committee

• REC reference

  13/LO/0273

• Date of REC Opinion

  5 Apr 2013

• REC opinion

  Further Information Favourable Opinion